nach oben

Erschienen in:

02.01.2023 | Narrative Review

How to use biomarkers of infection or sepsis at the bedside: guide to clinicians

verfasst von: Pedro Póvoa, Luís Coelho, Felipe Dal-Pizzol, Ricard Ferrer, Angela Huttner, Andrew Conway Morris, Vandack Nobre, Paula Ramirez, Anahita Rouze, Jorge Salluh, Mervyn Singer, Daniel A. Sweeney, Antoni Torres, Grant Waterer, Andre C. Kalil

Erschienen in: Intensive Care Medicine | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. In this context, biomarkers could be considered as indicators of either infection or dysregulated host response or response to treatment and/or aid clinicians to prognosticate patient risk. More than 250 biomarkers have been identified and evaluated over the last few decades, but no biomarker accurately differentiates between sepsis and sepsis-like syndrome. Published data support the use of biomarkers for pathogen identification, clinical diagnosis, and optimization of antibiotic treatment. In this narrative review, we highlight how clinicians could improve the use of pathogen-specific and of the most used host-response biomarkers, procalcitonin and C-reactive protein, to improve the clinical care of patients with sepsis. Biomarker kinetics are more useful than single values in predicting sepsis, when making the diagnosis and assessing the response to antibiotic therapy. Finally, integrated biomarker-guided algorithms may hold promise to improve both the diagnosis and prognosis of sepsis. Herein, we provide current data on the clinical utility of pathogen-specific and host-response biomarkers, offer guidance on how to optimize their use, and propose the needs for future research.

Nur mit Berechtigung zugänglich

Singer M, Deutschman CS, Seymour CW et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801–810. https://doi.org/10.1001/jama.2016.0287CrossRefPubMedPubMedCentral

Phua J, Ngerng W, See K et al (2013) Characteristics and outcomes of culture-negative versus culture-positive severe sepsis. Crit Care 17:R202. https://doi.org/10.1186/cc12896CrossRefPubMedPubMedCentral

Vincent JL, Sakr Y, Singer M et al (2020) Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA 323:1478–1487. https://doi.org/10.1001/jama.2020.2717CrossRefPubMedPubMedCentral

Povoa P, Martin-Loeches I, Ramirez P et al (2016) Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study. Ann Intensive Care 6:32. https://doi.org/10.1186/s13613-016-0134-8CrossRefPubMedPubMedCentral

Parlato M, Philippart F, Rouquette A et al (2018) Circulating biomarkers may be unable to detect infection at the early phase of sepsis in ICU patients: the CAPTAIN prospective multicenter cohort study. Intensive Care Med 44:1061–1070. https://doi.org/10.1007/s00134-018-5228-3CrossRefPubMed

Coelho LM, Salluh JI, Soares M et al (2012) Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study. Crit Care 16:R53. https://doi.org/10.1186/cc11291CrossRefPubMedPubMedCentral

Povoa P, Coelho L, Almeida E et al (2005) Pilot study evaluating C-reactive protein levels in the assessment of response to treatment of severe bloodstream infection. Clin Infect Dis 40:1855–1857. https://doi.org/10.1086/430382CrossRefPubMed

Povoa P, Coelho L, Almeida E et al (2005) C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study. Eur Respir J 25:804–812. https://doi.org/10.1183/09031936.05.00071704CrossRefPubMed

de Jong E, van Oers JA, Beishuizen A et al (2016) Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 16:819–827. https://doi.org/10.1016/S1473-3099(16)00053-0CrossRefPubMed

10.

Pierrakos C, Velissaris D, Bisdorff M et al (2020) Biomarkers of sepsis: time for a reappraisal. Crit Care 24:287. https://doi.org/10.1186/s13054-020-02993-5CrossRefPubMedPubMedCentral

11.

Evans L, Rhodes A, Alhazzani W et al (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 47:1181–1247. https://doi.org/10.1007/s00134-021-06506-yCrossRefPubMedPubMedCentral

12.

Nora D, Salluh J, Martin-Loeches I et al (2017) Biomarker-guided antibiotic therapy-strengths and limitations. Ann Transl Med 5:208. https://doi.org/10.21037/atm.2017.04.04CrossRefPubMedPubMedCentral

13.

Póvoa P, Coelho L, Bos LJ (2019) Biomarkers in pulmonary infections. Clin Pulm Med 26:118–125. https://doi.org/10.1097/cpm.0000000000000322CrossRef

14.

Conway Morris A, Bos LDJ, Nseir S (2022) Molecular diagnostics in severe pneumonia: a new dawn or false promise? Intensive Care Med 48:740–742. https://doi.org/10.1007/s00134-022-06722-0CrossRefPubMed

15.

Gentilotti E, De Nardo P, Cremonini E et al (2022) Diagnostic accuracy of point-of-care tests in acute community-acquired lower respiratory tract infections. A systematic review and meta-analysis. Clin Microbiol Infect 28:13–22. https://doi.org/10.1016/j.cmi.2021.09.025CrossRefPubMed

16.

Crobach MJ, Planche T, Eckert C et al (2016) European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect 22(Suppl 4):S63-81. https://doi.org/10.1016/j.cmi.2016.03.010CrossRefPubMed

17.

Haydour Q, Hage CA, Carmona EM et al (2019) Diagnosis of fungal infections. a systematic review and meta-analysis supporting American thoracic society practice guideline. Ann Am Thorac Soc 16:1179–1188. https://doi.org/10.1513/AnnalsATS.201811-766OCCrossRefPubMed

18.

Bloos F, Held J, Kluge S et al (2022) (1 –> 3)-beta-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial. Intensive Care Med 48(7):865–875. https://doi.org/10.1007/s00134-022-06733-xCrossRefPubMedPubMedCentral

19.

Del Corpo O, Butler-Laporte G, Sheppard DC et al (2020) Diagnostic accuracy of serum (1–3)-beta-D-glucan for Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect 26:1137–1143. https://doi.org/10.1016/j.cmi.2020.05.024CrossRefPubMed

20.

Chen F, Qasir D, Morris AC (2022) Invasive pulmonary aspergillosis in hospital and ventilator-associated pneumonias. Semin Respir Crit Care Med 43:234–242. https://doi.org/10.1055/s-0041-1739472CrossRefPubMed

21.

Temfack E, Rim JJB, Spijker R et al (2021) Cryptococcal antigen in serum and cerebrospinal fluid for detecting cryptococcal meningitis in adults living with human immunodeficiency virus: systematic review and meta-analysis of diagnostic test accuracy studies. Clin Infect Dis 72:1268–1278. https://doi.org/10.1093/cid/ciaa1243CrossRefPubMed

22.

Rouze A, Loridant S, Poissy J et al (2017) Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial. Intensive Care Med 43:1668–1677. https://doi.org/10.1007/s00134-017-4932-8CrossRefPubMed

23.

De Pascale G, Posteraro B, D’Arrigo S et al (2020) (1,3)-beta-D-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial. Crit Care 24:550. https://doi.org/10.1186/s13054-020-03265-yCrossRefPubMedPubMedCentral

24.

Reinhart K, Karzai W, Meisner M (2000) Procalcitonin as a marker of the systemic inflammatory response to infection. Intensive Care Med 26:1193–1200. https://doi.org/10.1007/s001340000624CrossRefPubMedPubMedCentral

25.

Dahaba AA, Elawady GA, Rehak PH et al (2002) Procalcitonin and proinflammatory cytokine clearance during continuous venovenous haemofiltration in septic patients. Anaesth Intensive Care 30:269–274. https://doi.org/10.1177/0310057X0203000302CrossRefPubMed

26.

Amour J, Birenbaum A, Langeron O et al (2008) Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of postoperative infection after vascular surgery. Crit Care Med 36:1147–1154. https://doi.org/10.1097/CCM.0b013e3181692966CrossRefPubMed

27.

Luyt CE, Combes A, Reynaud C et al (2008) Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive Care Med 34:1434–1440. https://doi.org/10.1007/s00134-008-1112-xCrossRefPubMed

28.

Meier MA, Branche A, Neeser OL et al (2019) Procalcitonin-guided antibiotic treatment in patients with positive blood cultures: a patient-level meta-analysis of randomized trials. Clin Infect Dis 69:388–396. https://doi.org/10.1093/cid/ciy917CrossRefPubMed

29.

Christ-Crain M, Opal SM (2010) Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 14:203. https://doi.org/10.1186/cc8155CrossRefPubMedPubMedCentral

30.

Kennis B, Ali A, Lasoff D et al (2022) The diagnostic utility of procalcitonin is limited in the setting of methamphetamine toxicity. Am J Emerg Med 54:36–40. https://doi.org/10.1016/j.ajem.2022.01.049CrossRefPubMed

31.

Simon L, Gauvin F, Amre DK et al (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:206–217. https://doi.org/10.1086/421997CrossRefPubMed

32.

Kondo Y, Umemura Y, Hayashida K et al (2019) Diagnostic value of procalcitonin and presepsin for sepsis in critically ill adult patients: a systematic review and meta-analysis. J Intensive Care 7:22. https://doi.org/10.1186/s40560-019-0374-4CrossRefPubMedPubMedCentral

33.

Wacker C, Prkno A, Brunkhorst FM et al (2013) Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 13:426–435. https://doi.org/10.1016/S1473-3099(12)70323-7CrossRefPubMed

34.

Layios N, Lambermont B, Canivet JL et al (2012) Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Crit Care Med 40:2304–2309. https://doi.org/10.1097/CCM.0b013e318251517aCrossRefPubMed

35.

Kalil AC, Metersky ML, Klompas M et al (2016) Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American Thoracic Society. Clin Infect Dis 63:e61–e111. https://doi.org/10.1093/cid/ciw353CrossRefPubMedPubMedCentral

36.

Torres A, Niederman MS, Chastre J et al (2017) International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociacion Latinoamericana del Torax (ALAT). Eur Respir J 50:1700582. https://doi.org/10.1183/13993003.00582-2017CrossRefPubMed

37.

Rodriguez AH, Aviles-Jurado FX, Diaz E et al (2016) Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: a CHAID decision-tree analysis. J Infect 72:143–151. https://doi.org/10.1016/j.jinf.2015.11.007CrossRefPubMed

38.

Ingram PR, Inglis T, Moxon D et al (2010) Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection. Intensive Care Med 36:528–532. https://doi.org/10.1007/s00134-009-1746-3CrossRefPubMedPubMedCentral

39.

Self WH, Balk RA, Grijalva CG et al (2017) Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis 65:183–190. https://doi.org/10.1093/cid/cix317CrossRefPubMed

40.

Kamat IS, Ramachandran V, Eswaran H et al (2020) Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis 70:538–542. https://doi.org/10.1093/cid/ciz545CrossRefPubMed

41.

Seligman R, Meisner M, Lisboa TC et al (2006) Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care 10:R125. https://doi.org/10.1186/cc5036CrossRefPubMedPubMedCentral

42.

Tanriverdi H, Tor MM, Kart L et al (2015) Prognostic value of serum procalcitonin and C-reactive protein levels in critically ill patients who developed ventilator-associated pneumonia. Ann Thorac Med 10:137–142. https://doi.org/10.4103/1817-1737.151442CrossRefPubMedPubMedCentral

43.

Luyt CE, Guerin V, Combes A et al (2005) Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 171:48–53. https://doi.org/10.1164/rccm.200406-746OCCrossRefPubMed

44.

Seligman R, Seligman BG, Teixeira PJ (2011) Comparing the accuracy of predictors of mortality in ventilator-associated pneumonia. J Bras Pneumol 37:495–503CrossRefPubMed

45.

Jensen JU, Hein L, Lundgren B et al (2011) Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 39:2048–2058. https://doi.org/10.1097/CCM.0b013e31821e8791CrossRefPubMed

46.

Nobre V, Harbarth S, Graf JD et al (2008) Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 177:498–505. https://doi.org/10.1164/rccm.200708-1238OCCrossRefPubMed

47.

Pepper DJ, Sun J, Rhee C et al (2019) Procalcitonin-guided antibiotic discontinuation and mortality in critically Ill adults: a systematic review and meta-analysis. Chest 155:1109–1118. https://doi.org/10.1016/j.chest.2018.12.029CrossRefPubMedPubMedCentral

48.

Povoa P, Salluh JI (2012) Biomarker-guided antibiotic therapy in adult critically ill patients: a critical review. Ann Intensive Care 2:32. https://doi.org/10.1186/2110-5820-2-32CrossRefPubMedPubMedCentral

49.

Salluh JI, Povoa P, Soares M et al (2008) The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit Care 12:R76. https://doi.org/10.1186/cc6922CrossRefPubMedPubMedCentral

50.

Povoa P, Souza-Dantas VC, Soares M et al (2011) C-reactive protein in critically ill cancer patients with sepsis: influence of neutropenia. Crit Care 15:R129. https://doi.org/10.1186/cc10242CrossRefPubMedPubMedCentral

51.

Dahaba AA, Rehak PH, List WF (2003) Procalcitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Intensive Care Med 29:579–583. https://doi.org/10.1007/s00134-003-1664-8CrossRefPubMed

52.

Bota DP, Van Nuffelen M, Zakariah AN et al (2005) Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver. J Lab Clin Med 146:347–351. https://doi.org/10.1016/j.lab.2005.08.005CrossRefPubMed

53.

Povoa P, Coelho L, Almeida E et al (2006) Early identification of intensive care unit-acquired infections with daily monitoring of C-reactive protein: a prospective observational study. Crit Care 10:R63. https://doi.org/10.1186/cc4892CrossRefPubMedPubMedCentral

54.

Garvik OS, Povoa P, Magnussen B et al (2020) C-reactive protein and albumin kinetics before community-acquired bloodstream infections—a Danish population-based cohort study. Epidemiol Infect 148:e38. https://doi.org/10.1017/S0950268820000291CrossRefPubMedPubMedCentral

55.

Tan M, Lu Y, Jiang H et al (2019) The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis: a systematic review and meta-analysis. J Cell Biochem 120:5852–5859. https://doi.org/10.1002/jcb.27870CrossRefPubMed

56.

Povoa P (2008) Serum markers in community-acquired pneumonia and ventilator-associated pneumonia. Curr Opin Infect Dis 21:157–162. https://doi.org/10.1097/QCO.0b013e3282f47c32CrossRefPubMed

57.

Claessens YE, Debray MP, Tubach F et al (2015) Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am J Respir Crit Care Med 192:974–982. https://doi.org/10.1164/rccm.201501-0017OCCrossRefPubMed

58.

Coelho L, Povoa P, Almeida E et al (2007) Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 11:R92. https://doi.org/10.1186/cc6105CrossRefPubMedPubMedCentral

59.

Schmit X, Vincent JL (2008) The time course of blood C-reactive protein concentrations in relation to the response to initial antimicrobial therapy in patients with sepsis. Infection 36:213–219. https://doi.org/10.1007/s15010-007-7077-9CrossRefPubMed

60.

Moreno MS, Nietmann H, Matias CM et al (2010) C-reactive protein: a tool in the follow-up of nosocomial pneumonia. J Infect 61:205–211. https://doi.org/10.1016/j.jinf.2010.06.005CrossRefPubMed

61.

Povoa P, Garvik OS, Vinholt PJ et al (2020) C-reactive protein and albumin kinetics after antibiotic therapy in community-acquired bloodstream infection. Int J Infect Dis 95:50–58. https://doi.org/10.1016/j.ijid.2020.03.063CrossRefPubMed

62.

Oliveira CF, Botoni FA, Oliveira CR et al (2013) Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Crit Care Med 41:2336–2343. https://doi.org/10.1097/CCM.0b013e31828e969fCrossRefPubMed

63.

Uckay I, Garzoni C, Ferry T et al (2010) Postoperative serum pro-calcitonin and C-reactive protein levels in patients with orthopedic infections. Swiss Med Wkly 140:w13124. https://doi.org/10.4414/smw.2010.13124CrossRefPubMed

64.

von Dach E, Albrich WC, Brunel AS et al (2020) Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial. JAMA 323:2160–2169. https://doi.org/10.1001/jama.2020.6348CrossRef

65.

Borges I, Carneiro R, Bergo R et al (2020) Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers. Crit Care 24:281. https://doi.org/10.1186/s13054-020-02946-yCrossRefPubMedPubMedCentral

66.

Bouadma L, Luyt CE, Tubach F et al (2010) Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375:463–474. https://doi.org/10.1016/S0140-6736(09)61879-1CrossRefPubMed

67.

Stolz D, Smyrnios N, Eggimann P et al (2009) Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 34:1364–1375. https://doi.org/10.1183/09031936.00053209CrossRefPubMed

68.

Arulkumaran N, Khpal M, Tam K et al (2020) Effect of antibiotic discontinuation strategies on mortality and infectious complications in critically Ill septic patients: a meta-analysis and trial sequential analysis. Crit Care Med 48:757–764. https://doi.org/10.1097/CCM.0000000000004267CrossRefPubMed

69.

Povoa P, Kalil AC (2020) Any role for biomarker-guide algorithms in antibiotic stewardship programs? Crit Care Med 48:775–777. https://doi.org/10.1097/CCM.0000000000004295CrossRefPubMed

70.

Sawyer RG, Claridge JA, Nathens AB et al (2015) Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med 372:1996–2005. https://doi.org/10.1056/NEJMoa1411162CrossRefPubMedPubMedCentral

71.

Yahav D, Franceschini E, Koppel F et al (2019) Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial. Clin Infect Dis 69:1091–1098. https://doi.org/10.1093/cid/ciy1054CrossRefPubMed

72.

Pugh R, Grant C, Cooke RP et al (2015) Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007577.pub3CrossRefPubMedPubMedCentral

73.

Montravers P, Tubach F, Lescot T et al (2018) Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: the DURAPOP randomised clinical trial. Intensive Care Med 44:300–310. https://doi.org/10.1007/s00134-018-5088-xCrossRefPubMed

74.

Salluh JI, Nobre V, Povoa P (2014) Using procalcitonin to guide antimicrobial duration in sepsis: asking the same questions will not bring different answers. Crit Care 18:142. https://doi.org/10.1186/cc13870CrossRefPubMedPubMedCentral

75.

Annane D, Maxime V, Faller JP et al (2013) Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open 3:e002186. https://doi.org/10.1136/bmjopen-2012-002186CrossRefPubMedPubMedCentral

76.

Bloos F, Trips E, Nierhaus A et al (2016) Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Intern Med 176:1266–1276. https://doi.org/10.1001/jamainternmed.2016.2514CrossRefPubMed

77.

Shapiro NI, Trzeciak S, Hollander JE et al (2009) A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit Care Med 37:96–104. https://doi.org/10.1097/CCM.0b013e318192fd9dCrossRefPubMed

78.

Mearelli F, Fiotti N, Giansante C et al (2018) Derivation and validation of a biomarker-based clinical algorithm to rule out sepsis from noninfectious systemic inflammatory response syndrome at emergency department admission: a multicenter prospective study. Crit Care Med 46:1421–1429. https://doi.org/10.1097/CCM.0000000000003206CrossRefPubMed

Titel: How to use biomarkers of infection or sepsis at the bedside: guide to clinicians
verfasst von: Pedro Póvoa
Luís Coelho
Felipe Dal-Pizzol
Ricard Ferrer
Angela Huttner
Andrew Conway Morris
Vandack Nobre
Paula Ramirez
Anahita Rouze
Jorge Salluh
Mervyn Singer
Daniel A. Sweeney
Antoni Torres
Grant Waterer
Andre C. Kalil
Publikationsdatum: 02.01.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Intensive Care Medicine / Ausgabe 2/2023
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-022-06956-y

Neu im Fachgebiet AINS

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

How to use biomarkers of infection or sepsis at the bedside: guide to clinicians

Abstract

Neu im Fachgebiet AINS

Mehr Frauen im OP – weniger postoperative Komplikationen

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Delir bei kritisch Kranken – Antipsychotika versus Placebo

Klinikreform soll zehntausende Menschenleben retten

Update AINS

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Close collaboration between pathologists and intensivists to understand (not just) coronavirus disease

Gymnopédie: music in the ICU

Multidrug-resistant bacteria in the grey shades of immunosuppression

Correction: High arterial oxygen levels and supplemental oxygen administration in traumatic brain injury: insights from CENTER-TBI and OzENTER-TBI

Relationship between immunosuppression and intensive care unit-acquired colonization and infection related to multidrug-resistant bacteria: a prospective multicenter cohort study

ICU scoring systems

Neu im Fachgebiet AINS

Mehr Frauen im OP – weniger postoperative Komplikationen

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Delir bei kritisch Kranken – Antipsychotika versus Placebo

Klinikreform soll zehntausende Menschenleben retten

Update AINS